Abstract
The present review summarizes the synthetic strategies to functionalized bridgehead nitrogen heteroannulated 1,2,4-triazine systems as well as their regiospecific and pharmacological properties.
Keywords: 1, 2, 4-Triazine, bridgehead nitrogen, heteroannulated, pharmacological properties
Current Organic Synthesis
Title:1,2,4-Triazine Chemistry Part III: Synthetic Strategies to Functionalized Bridgehead Nitrogen Heteroannulated 1,2,4-Triazine Systems and their Regiospecific and Pharmacological Properties
Volume: 10 Issue: 1
Author(s): Reda M. Abdel-Rahman, Mohamed S. T. Makki, Tarik E. Ali and Magdy A. Ibrahim
Affiliation:
Keywords: 1, 2, 4-Triazine, bridgehead nitrogen, heteroannulated, pharmacological properties
Abstract: The present review summarizes the synthetic strategies to functionalized bridgehead nitrogen heteroannulated 1,2,4-triazine systems as well as their regiospecific and pharmacological properties.
Export Options
About this article
Cite this article as:
M. Abdel-Rahman Reda, S. T. Makki Mohamed, E. Ali Tarik and A. Ibrahim Magdy, 1,2,4-Triazine Chemistry Part III: Synthetic Strategies to Functionalized Bridgehead Nitrogen Heteroannulated 1,2,4-Triazine Systems and their Regiospecific and Pharmacological Properties, Current Organic Synthesis 2013; 10 (1) . https://dx.doi.org/10.2174/1570179411310010006
DOI https://dx.doi.org/10.2174/1570179411310010006 |
Print ISSN 1570-1794 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6271 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
HIV-1 Infection In Children: A Clinical and Immunologic Overview
Current HIV Research Anti-Cancer Drugs of Today and Tomorrow: Are we Close to Making the Turn from Treating to Curing Cancer?
Current Pharmaceutical Design Utilising Nanotechnology and Nanosystems for Treatment of Rare Diseases
Pharmaceutical Nanotechnology Genetic Determinants of Amyotrophic Lateral Sclerosis as Therapeutic Targets
CNS & Neurological Disorders - Drug Targets Targeted Inhibition of Angiogenic Factors in AIDS-related Disorders
Current Drug Targets - Infectious Disorders Genistein Down-Regulates miR-223 Expression in Pancreatic Cancer Cells
Current Drug Targets Gene Expression Abnormalities in Thymoma
Current Pharmacogenomics Editorial (Hot Topic: Targeted Therapies in the Treatment of Breast Cancer and Localized Sarcomas)
Current Medicinal Chemistry Pharmacokinetic Evaluation of Callistemon viminalis Derived Natural Compounds as Targeted Inhibitors Against δ -Opioid Receptor and Farnesyl Transferase
Letters in Drug Design & Discovery Prothymosin α and its C-Terminal Immunoreactive Decapeptide Show No Evidence of Acute Toxicity: A Preliminary <i>In Silico</i>, <i>In Vitro</i> and <i>In Vivo</i> Investigation
Current Medicinal Chemistry Cancer and the Endogenous “Pineal Clock”: A Means of Early Diagnosis and Successful Treatment as Well as Prevention of Cancers
Current Aging Science Radioimmunotherapy of Solid Tumors: Searching for the Right Target
Current Drug Delivery Does Ligand Symmetry Play a Role in the Stabilization of DNA G-Quadruplex Host-Guest Complexes?
Current Medicinal Chemistry Targeting the Atypical Chemokine Receptor ACKR3/CXCR7: Phase 1 - Phage Display Peptide Identification and Characterization
Current Topics in Medicinal Chemistry Targeting Focal Adhesion Kinase in Neuroblastoma
Anti-Cancer Agents in Medicinal Chemistry Effects of Iron Chelation in Osteosarcoma
Current Cancer Drug Targets 3D Culture Modelling: An Emerging Approach for Translational Cancer Research in Sarcomas
Current Medicinal Chemistry Therapeutic Approach of Primary Bone Tumours by Bisphosphonates
Current Pharmaceutical Design Codon Swapping of Zinc Finger Nucleases Confers Expression in Primary Cells and <i>In Vivo</i> from a Single Lentiviral Vector
Current Gene Therapy Peptidic Tumor Targeting Agents: The Road from Phage Display Peptide Selections to Clinical Applications
Current Pharmaceutical Design